Clinical trials
Immune Checkpoint Therapy clinical trials
Below are recruiting immune checkpoint therapy clinical trials, each written for real people, not researchers. We’re tracking 152 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06487663Recruiting
TACE plus immunotherapy for untreated liver cancer
This study tests combining TACE (a procedure to block the tumor's blood supply) with immunotherapy drugs for liver cancer that has not spread outside the liver. It is for people who have not had any prior treatment for their liver cancer and are healthy enough for TACE.
TianjinAges 18–75 - NCT06502691RecruitingPhase 1/Phase 2
New imaging test to measure PARP in metastatic breast cancer
This trial tests a new imaging scan called [18F]FTT PET that may show how much of a protein called PARP is in your tumors. This could help doctors decide if a PARP inhibitor (a type of targeted therapy) is right for you. You may be able to join if you have metastatic breast cancer and are already planning to take a PARP inhibitor.
Seattle, WashingtonAges 18 years+ - NCT06519292Recruiting
Heart side effects from immunotherapy in cancer patients
This trial looks at whether immunotherapy drugs (checkpoint inhibitors) cause heart problems in people with certain cancers. It will help doctors understand who is at risk and how to monitor for side effects.
Amsterdam, North HollandAges 50 years+ - NCT06576921RecruitingPhase 2
Study of serplulimab with chemo before surgery for stomach cancer
This trial tests if adding serplulimab to standard chemotherapy before surgery can help shrink locally advanced stomach or gastroesophageal junction cancer. It aims to improve treatment outcomes for patients who are candidates for surgery.
Shijiazhuang, Heibei ProvinceAges 18–75 - NCT06580574RecruitingPhase 2
Immunotherapy to save the stomach or colon from surgery
This trial tests whether using immune checkpoint inhibitors alone (like checkpoint blockade drugs) can help people with certain gastric or colon cancers avoid surgery. It's for patients whose tumors have a specific genetic feature called dMMR/MSI-H and haven't spread to other parts of the body.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06581406RecruitingPhase 2/Phase 3
RP2 with nivolumab for untreated uveal melanoma
This clinical trial tests a new treatment called RP2 (a virus that attacks cancer cells) combined with nivolumab (an immunotherapy drug) for people with metastatic uveal melanoma who have never had immunotherapy before. It aims to see if this combination can shrink tumors and improve outcomes.
Scottsdale, ArizonaAges Any age - NCT06675201RecruitingPhase 2
Personalized vaccine for advanced esophageal cancer after treatment
This trial tests a personalized vaccine made from your tumor's unique markers (neoantigens) to help prevent your advanced esophageal cancer from coming back. It's for people who have already completed strong treatment and are currently cancer-free, but have a high risk of recurrence.
Chengdu, Please SelectAges 18–80 - NCT06730503Recruiting
Glycoprotein test for lung cancer immunotherapy response
This study looks at whether certain glycoproteins in your blood can help predict how well immunotherapy works for advanced non-small cell lung cancer. You would give blood samples before and after starting an immune checkpoint inhibitor treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06807593RecruitingPhase 2
Treating ICI-related diarrhea or colitis with ustekinumab
This trial tests if ustekinumab can help cancer patients who have diarrhea or colitis caused by immune checkpoint inhibitors. It may be an option if standard treatments haven't worked or aren't suitable.
Houston, TexasAges 18 years+ - NCT06818149Recruiting
Studying heart inflammation from immunotherapy in lung cancer
This study looks for specific markers in the blood that can help doctors better understand and treat heart inflammation (myocarditis) caused by immunotherapy in people with lung cancer. If you join, you will help find ways to improve care for other patients.
ShanghaiAges 18 years+ - NCT06852287RecruitingPhase 2
Study of chemo, targeted therapy, and immunotherapy for bile duct and gallbladder cancer
This trial tests a combination of chemotherapy directly to the liver, a targeted therapy pill, and an immunotherapy drug for people with advanced bile duct or gallbladder cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink or control the cancer.
Tianjin, TiaAges 18 years+ - NCT06951646RecruitingPhase 2
Personalized treatment for advanced lung cancer with long response to first-line therapy
This trial tests a combination of ivonescimab and docetaxel for people with advanced non-small cell lung cancer who have had a long response (11-15 months without the cancer getting worse) to first-line immunotherapy. The goal is to see if adjusting treatment based on ctDNA-MRD levels can improve outcomes.
ChangshaAges 18–75 - NCT06960577RecruitingPhase 3
Durvalumab with chemo before and after bladder cancer surgery
This trial tests a combination of durvalumab (an immunotherapy) with standard chemotherapy before and after bladder removal surgery for muscle-invasive bladder cancer. It aims to see if adding durvalumab helps improve outcomes while keeping side effects manageable.
ChermsideAges 18 years+ - NCT07003009Recruiting
Immunotherapy washout study for invasive ductal breast cancer
This study looks at how long it takes for a type of immunotherapy drug to clear out of your body in women with invasive ductal breast cancer who are about to start treatment before surgery. It may help doctors decide the best timing for future treatments.
IstanbulAges 18 years+ - NCT07003334Recruiting
Study on mental health and immune therapy for stomach cancer
This study looks at how psychological distress relates to immune checkpoint inhibitors in people with stomach cancer. It may help understand if emotional well-being affects treatment response.
Guangzhou, GuangdongAges 18–75 - NCT07130032RecruitingPhase 2
Immunotherapy combo for advanced lung cancer or melanoma
This trial tests a combination of immunotherapy drugs (anti-PD-1/PD-L1 antibodies) plus bevacizumab and a low-dose chemotherapy called cyclophosphamide for people with advanced lung cancer or melanoma who have already been on immunotherapy and their cancer has progressed.
Saint Petersburg, Sankt-PeterburgAges 18 years+ - NCT07138222Recruiting
Immune therapy and fertility in women and men with melanoma
This study looks at how immune checkpoint inhibitors (a type of immunotherapy) affect fertility and hormone health in premenopausal women and men with melanoma. It aims to understand and manage these side effects while you receive treatment.
Sydney, New South WalesAges 18–60 - NCT07141056Recruiting
Emotional stress and immunotherapy for liver cancer
This study looks at how emotional stress affects how well immunotherapy works for liver cancer. It is for people with liver cancer who are about to start immunotherapy, either before or after surgery, or as first treatment for advanced cancer.
Zhanjiang, GuangdongAges 18 years+ - NCT07161310Recruiting
Urolithin A with immunotherapy for newly diagnosed solid tumors
This trial tests adding a natural supplement called urolithin A to standard first-line immunotherapy for people with newly diagnosed solid tumors who have not yet had any cancer treatment. The goal is to see if it makes the immunotherapy work better.
FrankfurtAges 18 years+ - NCT07186621RecruitingPhase 3
Testing immunotherapy or chemoembolization after liver cancer surgery
This trial compares two treatments after liver cancer surgery to see which better prevents the cancer from coming back. You may be eligible if your surgery had a narrow margin and you have certain risk factors, like a tumor over 5 cm or high AFP levels.
BeijingAges 18–80 - NCT07257653RecruitingPhase 2
Cetuximab beta plus fruquintinib with or without immunotherapy for first-line advanced colorectal cancer
This trial tests a combination of two targeted drugs (cetuximab beta and fruquintinib) with or without an immunotherapy drug for people with a specific type of advanced colorectal cancer that has not been treated before. It aims to see if this approach is safe and effective for those whose tumors have certain genetic markers (RAS and BRAF wild type).
Hangzhou, ZhejiangAges 10–85 - NCT07339488RecruitingPhase 2
Low-dose radiation plus immunotherapy to shrink esophageal cancer before surgery
This trial tests whether a combination of low-dose radiation and immunotherapy can shrink advanced esophageal cancer enough to make it removable by surgery. It is for people whose cancer is considered borderline resectable or unresectable due to its location or spread.
Shantou, GuangdongAges 18–75 - NCT07389876Recruiting
Second-line treatment for advanced stomach cancer with nab-paclitaxel
This trial tests a new chemotherapy combination for patients with advanced stomach cancer that has worsened after initial treatment. It aims to find a better second-line option using a drug called nab-paclitaxel.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07421869Recruiting
Recovery from immune therapy-related hypothyroidism
This trial looks at whether patients can recover from low thyroid function caused by immune checkpoint inhibitor drugs. If you've finished immune therapy and are on thyroid medication, you may be able to stop or reduce it.
Seongnam-siAges 19 years+
Hear when a new Immune Checkpoint Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immune checkpoint therapy?
- Yes. Clin2 currently lists 152 recruiting immune checkpoint therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immune checkpoint therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immune checkpoint therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.